Document:

<PAGE>

                                                           EXHIBIT 10.14

                             FIRST AMENDMENT TO THE
                 AMGEN NONQUALIFIED DEFERRED COMPENSATION PLAN

         The Amgen Nonqualified Deferred Compensation Plan ("Plan") is hereby
clarified, in part, and amended, in part, as follows. Each particular is
effective as of January 1, 2002 unless otherwise noted.

1.       The Plan's title page is amended by adding "Amgen" before "Nonqualified
         Deferred Compensation Plan Effective January 1, 2002".

2.       The Plan is amended in its entirety by deleting the "," between "Amgen"
         and "Inc.", wherever it is found.

3.       Section 1.2 is amended and clarified to read as follows:

                  "Annual Base Salary" shall mean the wages, salaries, fees for
                  professional services, and other amounts received (without
                  regard to whether or not an amount is paid in cash) for
                  personal services actually rendered in the course of
                  employment with any Employer to the extent that the amounts
                  are includable in gross income (including, but not limited to,
                  compensation for services on the basis of a percentage of
                  profits, commissions on reimbursements or other expense
                  allowances under a nonaccountable plan (as described in
                  Treasury Regulation Section 1.62-2(c)), but excluding any
                  "goods and services allowance" provided to certain expatriate
                  staff members. Notwithstanding anything else in the Plan to
                  the contrary, Annual Base Salary shall not include the Annual
                  Bonus. Annual Base Salary shall be computed without regard to
                  any election to reduce or defer salary under the Amgen
                  Retirement and Savings Plan or any cafeteria plan under
                  Section 125 of the Code. Annual Base Salary shall not include:
                  (a) any Company contributions to the Amgen Retirement and
                  Savings Plan or any other employee benefit plan for or on
                  account of the Employee, except as otherwise provided in the
                  preceding sentence or (b) the items described in Treasury
                  Regulation Section 1.415-2(d)(3), which, among other items,
                  would exclude from compensation amounts realized from the
                  exercise of a nonqualified stock option ) or when restricted
                  stock (or property) held by an Employee either becomes freely
                  transferable or is no longer subject to a substantial risk of
                  forfeiture under Section 83 of the Code) and amounts realized
                  from the sale, exchange or other disposition of stock acquired
                  under a qualified stock option.

4.       Section 1.3 is clarified to read as follows:

                  "Annual Bonus" shall mean the wages, salaries, fees for
                  professional services, and other amounts received (without
                  regard to whether or not an amount is paid in cash) for
                  personal services actually rendered in the course of
                  employment with any Employer to the extent that the amounts
                  are commissions paid to salespeople or are paid pursuant to
                  the Amgen Performance Based Management Incentive

<PAGE>

                  Plan (MIP), the Amgen Inc. Executive Incentive Plan (EIP) or
                  an equivalent bonus program.

5.       Section 1.35 is amended to read as follows:

                  "Trust" shall mean one or more trusts established pursuant to
                  that certain Trust Agreement, dated as of January 1, 2002
                  between the Company and the trustee named therein, as amended
                  from time to time.

6.       Section 2.1 is clarified to read as follows:

                  SELECTION BY COMMITTEE. Participation in the Plan shall be
                  limited to a select group of Employees of the Employers, each
                  of whom is a member of management or is highly compensated and
                  to the members of the Board. From the group of Employees who
                  are management or highly compensated, the Committee shall
                  select, in its sole discretion, Employees to participate in
                  the Plan.

7.       Subsection 3.2(a) is clarified to read as follows:

                  (a)      ANNUAL BASE SALARY AND ANNUAL BONUS. For each Plan
                           Year, a Participant may elect to defer, as his or her
                           Annual Deferral Amount, Annual Base Salary or Annual
                           Bonus up to the following maximum percentages for
                           each deferral elected as determined by the Committee
                           for each Plan Year:

<TABLE>
<CAPTION>
     DEFERRAL        MAXIMUM PERCENTAGE
------------------   ------------------
<S>                  <C>
Annual Base Salary          50%
Annual Bonus               100%
</TABLE>

8.       Subsection 3.7(c) is amended, effective as of January 1, 2003, to read
         as follows:

                  MEASUREMENT FUNDS. From time to time, the Committee in its
                  sole discretion shall select and announce to Participants its
                  selection of mutual funds, insurance company separate
                  accounts, indexed rates or other methods (each, a "Measurement
                  Fund"), for the purpose of providing the basis on which gains
                  and losses shall be attributed to Account Balances under the
                  Plan. The Committee may, in its sole discretion, discontinue,
                  substitute or add a Measurement Fund at any time. Each such
                  action shall take effect after a reasonable period of time
                  following the day on which Participants are given written
                  notice of such change.

<PAGE>

9.       Section 4.1 is clarified to read as follows:

                  SHORT-TERM PAYOUT. In connection with each election to defer
                  an Annual Deferral Amount, a Participant may irrevocably elect
                  to receive a future "Short-Term Payout" from the Plan with
                  respect to such Annual Deferral Amount. Subject to the
                  Deduction Limitation, the Short-Term Payout shall be a lump
                  sum payment in an amount that is equal to the Annual Deferral
                  plus amounts credited or debited in the manner provided in
                  Section 3.7 above on that amount, determined at the time that
                  the Short-Term Payout becomes payable (rather than the date of
                  a Termination of Employment). Subject to the Deduction
                  Limitation and the other terms and conditions of the Plan,
                  each Short-Term Payout elected shall be paid out during a
                  60-day period commencing immediately after the last day of any
                  Plan Year designated by the Participant that is at least three
                  Plan Years after the Plan Year in which the Annual Deferral
                  Amount is actually deferred.

To record this First Amendment to the Plan as set forth herein, the Company has
caused its authorized officer to execute this document on this 5th day of
January, 2004.

                                       AMGEN INC.

                                       By: /s/ Brian McNamee
                                       ---------------------------------

                                       Title: Senior Vice President, Human
                                       Resources<PAGE>

                                                           EXHIBIT 10.53

* CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY THE
BRACKETS, HAS BEEN OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

                   AMENDMENT NO. 1 TO ENBREL SUPPLY AGREEMENT

         This AMENDMENT NO. 1 TO ENBREL SUPPLY AGREEMENT (this "Amendment") is
entered into effective as of the 20th day of September 2002 by and between
Genentech Inc., a Delaware corporation ("Genentech") and Immunex Corporation, a
Washington corporation and a wholly-owned subsidiary of Amgen Inc. ("Immunex"),
and amends that certain Enbrel Supply Agreement entered into by Genentech and
Immunex on April 12, 2002 (the "Agreement").

         For good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, Genentech and Immunex (the "Parties") agree as
follows:

1.       Section 5.2(b) of the Agreement is amended to read in its entirety as
         follows:

         "5.2 (b) Completion of Milestone II: Final Release of Third Successful
         Qualification Batch of Bulk Drug: Immunex shall pay Genentech [*]
         Dollars ($[*]) upon the completion of Milestone II, provided that [*];
         and, in addition, Genentech shall also be entitled to receive
         additional payments of [*], which such additional payment amounts shall
         be payable upon [*]. [*]."

2.       All capitalized terms not defined herein shall have the meaning set
         forth in the Agreement.

3.       Except as set forth herein, all other terms of the Agreement remain in
         full force and effect.

4.       This Amendment may be executed in counterparts, each of which shall be
         deemed an original, and all of which, taken together, shall constitute
         one and the same instrument. This Amendment shall be effective upon
         full execution by facsimile or original, and a facsimile signature
         shall be deemed to be and shall be as effective as an original
         signature. This Amendment may not be amended except by a written
         instrument duly executed and delivered by both Parties.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment effective as
of the date set forth above.

GENENTECH, INC.                                IMMUNEX CORPORATION

By:          /s/ David Eberman                 By:      /s/ Douglas Williams
    -------------------------------------          -----------------------------
David Eberman                                  Douglas Williams
Senior Vice President of Product Operations    Senior Vice President, Operations
Date: 9/24/2002                                Date: 9/20/2002

* Confidential Treatment Requested.

                                        1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]